You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Safety & Tolerability

Adverse events (AEs) through Week 48 (pooled) (data from the GEMINI-1 and -2 studies): 1

Go To Top Close

*2 deaths (acute myocardial infarction, n=1; Burkitt's lymphoma, n=1) in GEMINI-2 study; both were in the DTG + 3TC group and were considered unrelated to the study drug regimen. 1

Most common adverse events for TIVICAY + Lamivudine (pooled) (data from the GEMINI-1 and -2 studies): 1

Adverse events occurring in ≥5% of participants in either arm 1

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

References:

  1. Cahn P et al. Presented at: International AIDS Conference; July 23-27, 2018; Amsterdam, Netherlands.

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.